CJC-1295 without DAC results: what to expect and when

A peptide intended to trigger growth hormone release, with no human dosing study found.

Also called: Modified GRF 1-29, Mod GRF 1-29, Mod GRF(1-29), CJC-1295 no DAC.

GHRH analogues · Modified GHRH 1-29 analogue without an albumin-binding DAC tag.

No human dosing study found for modified GRF 1-29; DAC trials tested another molecule. Lab tests and forums do not prove safety or benefits.

Key studies

Henninge 2010: seized peptide: A marketed name did not establish that a preparation contained the DAC molecule used in human trials. (source)
Gajda 2019: altered GRF in seizures: Seized material included altered peptide sequences; a familiar name alone cannot establish identity. (source)

Related to CJC-1295 without DAC

Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
CJC-1295 with DAC: An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
Ipamorelin: An experimental peptide that triggers growth hormone release.

Sources

21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
503B Bulk Drug Substances List, FDA · FDA · 2026
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
Medicines, European Medicines Agency · European Medicines Agency · 2026
The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
EGRIFTA WR (tesamorelin) for injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
Supply unlicensed medicinal products (specials), MHRA · 2025
December 4, 2024 Pharmacy Compounding Advisory Committee Meeting, FDA · 2024
FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting December 4, 2024, US Food and Drug Administration · 2024
Low blood sugar (hypoglycaemia), NHS · 2023
Anticoagulant medicines - Side effects, NHS
DailyMed - GLUCOTROL XL- glipizide tablet, extended release, Pfizer Inc. · DailyMed

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.